Article info
PDFCase Reports: Adverse drug reactions and complications
Cold agglutinin disease secondary to severe SARS-CoV-2 treated with eculizumab
- Correspondence to Dr Laura Federici; laura.federici85{at}gmail.com
Citation
Cold agglutinin disease secondary to severe SARS-CoV-2 treated with eculizumab
Publication history
- Accepted April 2, 2022
- First published April 29, 2022.
Online issue publication
April 29, 2022
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© BMJ Publishing Group Limited 2022. No commercial re-use. See rights and permissions. Published by BMJ.